Pivotal BioSciences Inc.
This article was originally published in Start Up
Executive Summary
With two product candidates in its portfolio--contortrostatin (an anti-angiogenic agent purified from snake venom), and a proprietary low-dose version of interleukin-2--Pivotal BioSciences hopes to be a catalyst for other university-based researchers in the Los Angeles area to develop their discoveries under its corporate umbrella.